communityacquir
respiratori
virus
carv
frequent
caus
diseas
solid
organ
transplant
sot
recipi
lower
respiratori
tract
infect
carv
associ
signific
morbid
even
mortal
popul
articl
review
clinic
manifest
carv
infect
summar
evidencebas
recommend
prevent
therapeut
strategi
decreas
burden
viral
infect
sot
recipi
influenzalik
symptom
influenza
season
wait
microbiolog
confirm
efficaci
ribavirin
aerosol
oral
treatment
rsv
infect
sot
recipi
determin
communityacquir
respiratori
virus
carv
frequent
caus
diseas
solid
organ
transplant
sot
recipi
lower
respiratori
tract
infect
carv
associ
signific
morbid
even
mortal
popul
impact
carv
infect
progress
chronic
allograft
dysfunct
lung
transplant
recipi
remain
controversi
among
carv
influenza
infect
may
particularli
present
sever
diseas
sot
recipi
main
risk
factor
sever
influenza
infect
shorter
time
transplant
presenc
pneumonia
nucleic
acid
amplif
test
nat
becom
main
diagnost
method
detect
carv
clinic
specimen
nat
significantli
sensit
method
direct
antigen
detect
viru
isol
cell
cultur
infect
control
measur
remain
essenti
element
decreas
burden
carv
sot
recipi
main
strategi
prevent
influenza
yearli
administr
inactiv
influenza
vaccin
highli
recommend
transplant
studi
shown
reduct
immunogen
influenza
vaccin
sot
recipi
degre
efficaci
expect
popul
role
palivizumab
ivig
prevent
respiratori
syncyti
viru
rsv
infect
sot
recipi
establish
use
antivir
therapi
neuraminidas
inhibitor
associ
improv
outcom
sot
recipi
irrespect
durat
symptom
antivir
therapi
empir
administ
sot
recipi
introduct
communityacquir
respiratori
viru
carv
infect
common
caus
medic
consult
hospit
solid
organ
transplant
sot
recipi
caus
varieti
rna
virus
includ
influenza
b
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
rhinoviru
hrv
human
metapneumoviru
hmpv
coronaviru
addit
dna
virus
adenoviru
polyomaviru
bocaviru
may
also
respons
case
respiratori
tract
infect
major
infect
due
carv
restrict
upper
respiratori
tract
urt
sot
recipi
due
alter
cellular
humor
immun
higher
risk
develop
progress
lower
respiratori
tract
lrt
carv
lrt
infect
associ
signific
morbid
sot
recipi
specif
lung
transplant
recipi
carv
lrt
infect
may
associ
higher
incid
chronic
lung
allograft
dysfunct
clad
although
literatur
topic
controversi
virus
share
similar
clinic
manifest
influenza
virus
appear
particularli
associ
impair
outcom
sot
recipi
influenza
pandem
led
epidemiolog
studi
assess
clinic
manifest
outcom
influenza
infect
well
clinic
trial
efficaci
prevent
strategi
influenza
includ
sot
recipi
also
routin
use
molecular
method
detect
carv
increas
knowledg
epidemiolog
direct
indirect
effect
sot
outcom
given
updat
knowledg
topic
panel
european
expert
manag
viral
infect
transplant
patient
develop
evidencebas
recommend
manag
carv
sot
recipi
influenza
acut
usual
selflimit
febril
ill
occur
everi
winter
season
infect
influenza
viru
occur
time
transplant
appear
sever
earli
posttranspl
period
month
risk
influenza
also
relat
type
organ
transplant
studi
involv
sot
recipi
incid
influenza
personyear
among
lung
kidney
liver
transplant
recipi
respect
similarli
studi
perform
pandem
document
incid
influenza
infect
higher
recipi
lung
case
per
personyear
recipi
organ
kidney
case
per
personyear
liver
case
per
personyear
heart
case
per
patientyear
fewer
data
avail
regard
epidemiolog
influenza
b
viru
infect
transplant
recipi
seri
report
influenza
b
viru
may
caus
onefourth
total
number
influenza
case
known
whether
influenza
b
viru
infect
may
associ
differ
outcom
sot
recipi
clinic
featur
influenza
sot
recipi
consider
differ
describ
gener
popul
influenza
clinic
suspect
sot
recipi
present
respiratori
symptom
fever
rhinorrhea
cough
sore
throat
without
myalgia
headach
dyspnoea
influenza
season
howev
fever
may
miss
usual
abrupt
onset
may
delay
immunocompromis
patient
therefor
propos
made
modifi
definit
influenzalik
ill
provid
ecdc
better
captur
present
immunocompromis
patient
basic
definit
carv
diseas
includ
new
onset
symptom
ii
least
one
follow
four
respiratori
symptom
cough
sore
throat
short
breath
coryza
iii
clinician
judgment
ill
due
infect
occurr
pneumonia
sot
recipi
influenza
infect
rang
bilater
involv
frequent
observ
bacteri
viral
fungal
coinfect
rel
common
sot
recipi
report
coinfect
frequenc
rang
increas
risk
acut
chronic
allograft
reject
also
associ
infect
influenza
respiratori
virus
lung
transplant
recipi
influenza
link
occurr
chronic
lung
allograft
dysfunct
clad
although
consist
studi
less
frequent
complic
influenza
sot
recipi
includ
enceph
myocard
myositi
influenza
sot
recipi
associ
high
rate
medic
complic
even
mortal
main
risk
factor
associ
impair
outcom
presenc
pneumonia
diabet
mellitu
use
antilymphocyt
globulin
month
delay
antivir
therapi
rsv
one
common
caus
respiratori
tract
infect
childhood
epidemiolog
clinic
characterist
rsv
infect
incomplet
determin
sot
recipi
studi
includ
lung
transplant
recipi
incid
rsv
infect
may
rang
carv
infect
occur
sot
recipi
clinic
manifest
rsv
infect
sot
recipi
includ
fever
cough
dyspnoea
groundglass
opac
lung
nodul
common
find
ct
scan
case
lrt
diseas
recent
data
suggest
rsv
infect
current
rare
caus
hospit
mortal
among
sot
recipi
lung
transplant
recipi
rsv
lrt
diseas
appear
contribut
develop
clad
associ
acut
reject
parainfluenza
paramyxoviru
four
speci
describ
show
pronounc
season
autumn
wherea
frequent
detect
spring
incid
piv
infect
sot
recipi
vari
carv
infect
clinic
manifest
piv
infect
sot
recipi
differ
seen
carv
infect
sever
case
piv
diseas
describ
especi
children
recent
studi
show
higher
incid
hospit
lung
transplant
recipi
piv
infect
compar
infect
carv
human
rhinoviru
picornaviru
frequent
caus
common
cold
gener
popul
sot
recipi
rhinoviru
respiratori
viru
commonli
identifi
prospect
studi
assess
incid
carv
infect
infect
rhinoviru
usual
mild
selflimit
although
case
sever
lrt
diseas
chronic
viral
shed
describ
lung
transplant
recipi
rhinoviru
appear
less
commonli
associ
clad
respiratori
virus
clinic
characterist
adenoviru
hmpv
coronaviru
infect
similar
seen
carv
clinic
signific
newli
discov
virus
polyomavirus
wu
ki
viru
bocaviru
transplant
popul
complet
determin
nucleic
acid
amplif
test
nat
becom
main
diagnost
method
detect
carv
clinic
specimen
nat
prove
significantli
sensit
method
direct
antigen
detect
viru
isol
cell
cultur
increas
sensit
also
associ
excel
specif
particularli
detect
amplifi
product
use
specif
probe
time
nat
frequent
base
realtim
pcr
technolog
present
theoret
follow
advantag
could
detect
viral
load
low
copi
genom
equival
introduc
amplif
reaction
analyt
specif
approach
techniqu
provid
semiquantit
result
challeng
carv
detect
relat
number
differ
agent
need
detect
may
encompass
differ
viral
speci
type
subtyp
depend
complet
screen
spectrum
agent
target
technic
solut
adopt
eg
multiplex
could
impact
perform
possibl
decreas
sensit
rapid
influenza
diagnost
test
appropri
specif
low
sensit
perform
diagnosi
influenza
particularli
clinic
decisionmak
antivir
therapi
immunocompromis
host
appear
suboptim
nasopharyng
specimen
collect
swab
conveni
effect
respiratori
specimen
initi
screen
viral
respiratori
virus
pool
nasopharyng
pharyng
specimen
use
could
possibl
increas
sensit
along
decreas
variabl
result
case
lrt
diseas
bronchoalveolar
lavag
bal
prefer
specimen
diagnost
test
carv
particularli
import
patient
lrt
diseas
may
present
neg
test
nasopharyng
swab
respiratori
specimen
standard
limit
abil
provid
reproduc
quantit
assay
although
realtim
technolog
offer
opportun
semiquantit
assess
viral
load
therefor
one
cautiou
overinterpret
quantit
result
also
durat
viral
shed
use
sensit
molecular
assay
significantli
longer
compar
immunocompet
adult
immunocompet
adult
expect
rapid
viral
clearanc
nucleic
acid
detect
neg
within
day
prolong
shed
week
month
common
occurr
highli
immunocompromis
individu
particularli
influenza
protocol
establish
best
frequenc
viral
test
appropri
cutoff
discontinu
antivir
therapi
sot
recipi
describ
tabl
infect
control
measur
remain
essenti
element
decreas
burden
carv
sot
recipi
overal
awar
among
healthcar
personnel
caregiv
potenti
deleteri
outcom
carv
infect
sot
recipi
import
earli
detect
infect
may
major
impact
incid
carv
infect
subsequ
complic
specif
hand
hygien
adher
contact
respiratori
droplet
isol
help
reduc
carv
infect
sot
recipi
infect
control
measur
need
taken
patient
sent
home
pcr
neg
influenza
viru
current
carv
prevent
vaccin
studi
assess
clinic
effect
influenza
vaccin
sot
recipi
report
overal
low
rate
clinic
failur
vaccin
rang
use
adjuv
vaccin
pandem
although
also
depend
match
vaccin
circul
strain
addit
patient
develop
symptomat
influenza
infect
vaccin
reduc
risk
subsequ
pneumonia
larg
registri
kidney
transplant
recipi
influenza
vaccin
first
year
transplant
associ
reduc
incid
graft
loss
mortal
howev
data
immunogen
influenza
vaccin
transplant
popul
controversi
publish
studi
suggest
reduc
humor
immun
respons
expect
sot
recipi
lung
transplant
recipi
appear
poorer
respons
recipi
allograft
probabl
relat
higher
degre
immunosuppress
need
lung
transplant
allogen
constel
virusinfect
host
cell
effector
cell
use
mycophenol
mofetil
mtor
inhibitor
relat
weaker
respons
influenza
vaccin
studi
other
respons
influenza
b
viru
usual
weaker
seen
influenza
virus
differ
strategi
propos
improv
immunogen
influenza
vaccin
sot
recipi
includ
administr
boost
dose
intraderm
vaccin
higher
dose
vaccin
antigen
use
adjuv
vaccin
adjuv
vaccin
adjuv
proven
improv
efficaci
elderli
overal
increas
immunogen
transplant
recipi
howev
enough
data
transplant
popul
current
recommend
specif
approach
household
member
healthcar
worker
contact
sot
recipi
also
receiv
influenza
vaccin
addit
pneumococc
vaccin
particularli
administr
pneumococc
conjug
vaccin
propos
sot
recipi
potenti
reduc
risk
influenzarel
complic
inactiv
influenza
vaccin
gener
well
toler
sot
recipi
report
pandem
found
increas
rate
de
novo
antihla
antibodi
administr
adjuv
influenza
vaccin
although
without
clinic
signific
year
subsequ
studi
confirm
result
influenza
vaccin
usual
recommend
month
transplant
order
avoid
tempor
relationship
vaccin
acut
reject
period
patient
higher
risk
allograft
reject
studi
shown
appropri
antibodi
respons
safeti
profil
also
vaccin
administ
first
week
posttranspl
overal
need
protect
influenza
sot
recipi
clearli
outweigh
theoret
safeti
concern
vaccin
vaccin
yet
avail
rsv
limit
experi
use
immunoprophylaxi
nonspecif
intraven
immunoglobulin
ivig
rsvivig
palivizumab
monoclon
antibodi
specif
rsvf
protein
prevent
rsv
infect
sot
recipi
palivizumab
may
consid
children
year
old
rsv
season
howev
high
cost
palivizumab
combin
lack
clear
evid
efficaci
sot
recipi
preclud
widescal
use
upper
respiratori
tract
diseas
caus
carv
symptomat
treat
analges
antiinflammatori
drug
nasal
decongest
due
risk
develop
rey
syndrom
salicyl
avoid
children
adolesc
influenzalik
symptom
case
lrt
diseas
includ
pneumonia
bacteri
fungal
infect
must
rule
appropri
treat
empir
antibiot
therapi
direct
streptococcu
pneumonia
haemophilu
influenza
staphylococcu
aureu
adequ
antivir
therapi
initi
soon
possibl
sot
recipi
suspect
influenza
infect
recommend
made
irrespect
durat
symptom
sever
ill
case
antivir
treatment
influenzalik
ill
delay
wait
microbiolog
confirm
rather
discontinu
appropri
test
result
neg
earli
specif
antivir
treatment
especi
encourag
case
pneumonia
two
class
antivir
drug
current
approv
treatment
influenza
infect
inhibitor
amantadin
rimantadin
activ
influenza
neuraminidas
inhibitor
oseltamivir
zanamivir
drug
investig
parenter
zanamivir
peramivir
inhibitor
current
recommend
due
resist
circul
influenza
strain
variabl
time
predomin
circul
influenza
b
neuraminidas
inhibitor
usual
well
toler
common
advers
effect
gastrointestin
symptom
children
use
oseltamivir
associ
neuropsychiatr
advers
event
inhal
zanamivir
two
puff
mg
twice
daili
requir
dose
adjust
either
hepat
renal
failur
oral
oseltamivir
mg
twice
daili
dose
adjust
need
hepat
impair
dose
modifi
renal
insuffici
accord
recommend
includ
tabl
proven
benefit
higher
dose
oseltamivir
sot
recipi
sever
influenza
infect
lack
avail
intraven
zanamivir
peramivir
consid
sot
recipi
sever
ill
despit
oral
oseltamivir
patient
oral
absorpt
concern
suspect
confirm
oseltamivir
resist
durat
antivir
therapi
day
mild
case
influenza
prolong
sever
case
protract
evolut
viral
load
nasopharyng
swab
undetect
pregnanc
contraind
administr
oseltamivir
pregnant
women
encourag
receiv
influenza
vaccin
develop
oseltamivir
resist
promot
lack
effici
immun
respons
high
viral
load
prolong
viral
shed
frequent
observ
immunocompromis
host
resist
suspect
prolong
shed
c
day
observ
resist
diagnos
special
laboratori
use
genotyp
phenotyp
assay
resist
oseltamivir
develop
strain
gener
crossresist
peramivir
remain
suscept
zanamivir
henc
parenter
zanamivir
compassion
use
option
transmiss
resist
strain
occasion
describ
highrisk
hospit
ward
crossresist
avail
neuraminidas
inhibitor
describ
underscor
need
new
therapi
use
ribavirin
treatment
rsv
infect
controversi
nevertheless
expert
consid
ribavirin
treatment
sever
form
lrt
diseas
sot
recipi
aerosol
ribavirin
administ
g
h
everi
h
g
hday
day
appropri
precaut
taken
avoid
environ
patient
treat
system
ribavirin
check
haemolysi
abnorm
liver
function
kidney
failur
note
data
potenti
impact
use
ribavirin
prevent
indirect
effect
lung
transplant
recipi
rsv
infect
treatment
sever
form
piv
infect
margin
experi
use
ribavirin
without
intraven
immunoglobulin
steroid
ribavirin
use
treatment
lrt
diseas
caus
coronaviru
outbreak
sever
acut
respiratori
syndrom
sar
howev
data
recommend
ribavirin
treatment
coronaviru
infect
sot
recipi
manag
sever
hmpv
infect
support
care
main
treatment
although
anecdot
report
publish
success
treatment
ribavirin
intraven
immunoglobulin
specif
treatment
approv
rhinoviru
infect
om
receiv
fund
research
roch
receiv
honoraria
merck
jc
receiv
fund
research
instituto
de
salud
carlo
iii
madrid
spain
receiv
honoraria
novarti
merck
pfizer
roch
author
conflict
declar
